DEEP Platform Showcases
Discover concise spotlights on high‑value digital measures - curated for teams needing fast, credible insight. Each article distills structured evidence from the DEEP Platform into clear takeaways you can use to assess relevance, maturity, and regulatory readiness. Perfect for teams evaluating new endpoints, shaping strategy, or exploring what 'good' looks like in digital measurement.
Calling for Collaborators - View latest engagement opportunities here!
March 2026 | Harmonization of Physical Activity Measurement Definitions: Join our Pfizer-led consortium, to establish cross-industry consensus on terminology and definitions for measures of physical activity.
Contact us to find out more | Read more about this opportunity
January 2026 | Navigating Health Technology Assessment (HTA) Expectations for Digital Measure Approval: Join our mission and take positive steps towards successful HTA interactions.
Contact us to find out more | Read more about this opportunity
General Showcase Items
Building Digital Measures for PD? DEEP can help! Clinical trials in PD have relied on snapshot, clinic-based assessments for too long. We're changing that: bringing pharma, biotech, researchers,...
Chronic respiratory diseases like COPD, asthma, and IPF are 24-hour conditions, yet clinical trials often rely solely on daytime measurements, leaving a critical evidence gap. Pharmaceutical leaders...
Mobility problems don't just affect movement; they erode self-confidence and increase the risk of hospitalization. While standard clinic tests capture a snapshot, they miss the 24-hour reality of...
Digital Measurement Solution
Respiratory Conditions
Rare Diseases
Sleep Quality
Nocturnal Monitoring
*Engagement Opportunity
Chronic respiratory diseases like COPD, asthma, and IPF are 24-hour conditions, yet clinical trials often rely solely on daytime measurements, leaving a critical evidence gap. Pharmaceutical leaders...
Developing precise and comprehensive digital measures for Myasthenia Gravis (MG) that capture meaningful aspects of the disease and address unmet needs in patient care and drug development.
Following the precedent set by successful GLP-1 trials in Obstructive Sleep Apnea (OSA), expansion of drug labels into this highly prevalent and impactful condition is the new frontier for metabolic...
Why is this important? Accelerating and widening access to safe, effective and innovative health technologies that bring value to patients and the healthcare system is essential for improving health...
A quick look at how Respiratory Rate (RR) connects the lived experience of COPD breathlessness with an objective digital signal. Relevant for Market Access teams, Data Scientists, IT/Digital Health...
.png?width=1024&height=1024&name=generated-image-1%20(6).png)







